Novosteo was founded to reduce the morbidity, mortality and loss of productivity associated with bone fractures. Based on discoveries of agents that accelerate bone regeneration and breakthroughs in methods to target these agents selectively to fracture surfaces, Novosteo has designed a series of fracture-targeted drugs that concentrate a drug’s healing power specifically at the fracture site, thereby greatly accelerating and improving the healing process. The mission of Novosteo is to reduce the debilitating and often life-threatening effects of bone fractures.
Stewart Low, Chief Scientific Officer and Founder, is the primary inventor of Novosteo’s technology. He has worked on the development of fracture-targeted drugs for the past ten years. He is a primary inventor of 7 patents related to Novosteo’s core technology. He has been instrumental in raising non-dilutive capital for Novosteo. Stewart has also spent time conducting research in the autoimmune division of Endocyte Inc. and in the device-testing group of Nelson Laboratories. He received his bachelor’s degree in microbiology from Brigham Young University in 2008 and his Ph.D. from the University of Utah in Bioengineering in 2015. Stewart has also worked as a postdoctoral research associate in the Chemistry department at Purdue University from 2015 until 2018.
William Boyle, CEO, has 30 years of pharmaceutical and biotechnology industry experience including leadership roles in private start-up and multinational companies. Dr. Boyle was previously served as the Chief of Translational Medicine for BioAtla inc. Before that Dr. Boyle was President of VivaMab a historical drug development division of BioAtla involved in the discovery and development of therapeutic antibodies. Prior to that he was founder, President and Chief Science Officer at AnaptysBio [NASDQ: ANAB], and former Director of Research at Amgen, Inc. where he led the discovery and early preclinical development of Denosumab, a RANKL-targeted therapeutic antibody approved for the treatment of osteoporosis (Prolia) and cancer (Xgeva). Dr. Boyle holds a Doctoral degree in Experimental Pathology from the UCLA School of Medicine and was a Howard Hughes Medical Institute Postdoctoral Fellow of the Life Sciences Research Foundation at the Salk Institute for Biological Studies.
Philip Low, Founder and Board Member, is the Presidential Scholar in Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. He has spent more than 40 years exploring novel methods of targeted drug development and characterizing the structure and function of the human erythrocyte membrane. During this period, he published over 450 scientific articles in peer-reviewed journals and holds over 150 US patents/patents pending. His pioneering drug-delivery research has focused on the design and synthesis of targeting ligands that have proven successful in the targeted delivery of therapeutic and imaging agents to both cancer cells and aberrant immune cells involved in inflammatory and autoimmune diseases. Eight drugs stemming from this research are currently undergoing human clinical trials and four companies (Novosteo, Endocyte, HuLow, and On Target Laboratories) have been founded to commercialize these discoveries. Philip has served on several National Institutes of Health Study Sections and has received an NIH Merit Award. He also received both of Purdue’s awards for outstanding research as well as the university’s highest career achievement recognition for a faculty member, the Morrill Award. Other awards received include the American Chemical Society’s (ACS) George & Christine Sosnovsky Award for Cancer Research, the Roland T. Lakey Award, the Mathias P. Mertes Award, and the American Association for Cancer Research (AACR) Award for Outstanding Achievement in Chemistry in Cancer Research. He was elected to the National Academy of Inventors in 2015. Philip received his BS in Chemistry from Brigham Young University in 1971 and his PhD in Biochemistry from the University of California, San Diego in 1975.
Daniel J. Hasler serves as the chair of the Novosteo board. Hasler served as the Secretary of Commerce for the State of Indiana and Chief Executive Officer of the Indiana Economic Development Corporation (IEDC). As Secretary of Commerce, Hasler attracted a record-breaking 254 companies to the State of Indiana in FY 2012. He has an extensive 31-year career at Eli Lilly and Co., a Fortune 500 global pharmaceutical company headquartered in Indianapolis. While at Eli Lilly, Hasler served in a number of leadership positions, most recently as Vice President for Global Marketing, and was responsible for the commercial strategy and market performance of Lilly’s pharmaceutical portfolio. While VP for Global Marketing Hasler oversaw the launch of Lilly’s osteoporosis drugs Forteo and Evista. He also was the Chief Marketing Officer for Eli Lilly USA. In 2010, Hasler was the recipient of the Lilly Lifetime Achievement Award.